Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Symlin® Dose Escalation Efficacy vs. Conventional Therapy in Type 2 Diabetes Mellitus

NCT01137695 is registered in ClinicalTrials.gov with Cheryl Rosenfeld, DO as lead sponsor.

NCT NCT01137695
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01137695 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Symlin® Dose Escalation Efficacy vs. Conventional Therapy in Type 2 Diabetes Mellitus
Lead sponsor
Cheryl Rosenfeld, DO
Phase
Phase 3
Overall status
Unknown status
Start date
May 31, 2010
Completion date
April 30, 2012
Enrollment
40 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes mellitus